Enzyme Therapy and Inhibitors as Drugs — MCQs

10 questions

A child presents with bone pain and hepatosplenomegaly, indicative of Gaucher's disease. A trephine biopsy and aspirate show the following finding. Which of the following is the most likely enzyme deficient in this condition?

Statins act on:

Which of the following anti-gout drugs acts by inhibiting the enzyme xanthine oxidase?

Enzyme replacement therapy is available for which of the following lysosomal storage disorders?

Which enzyme is irreversibly inhibited by aspirin?

A patient presents with hyperuricemia and gout. Which enzyme's overactivity is most likely associated?

Resistance to Methotrexate develops due to?

Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

HMG-CoA reductase is inhibited by:

Q10

Km increases, but Vmax remains same. This is which type of inhibition?

Enzyme Therapy and Inhibitors as Drugs Indian Medical PG Practice Questions and MCQs

Question 1: A child presents with bone pain and hepatosplenomegaly, indicative of Gaucher's disease. A trephine biopsy and aspirate show the following finding. Which of the following is the most likely enzyme deficient in this condition?

A. Hexosaminidase
B. Glucocerebrosidase (Correct Answer)
C. Sphingomyelinase
D. Alpha 1,4-glucosidase

Explanation: ***Correct: Glucocerebrosidase*** - The clinical presentation of **bone pain**, **hepatosplenomegaly**, and the characteristic histological finding of **lipid-laden macrophages** (Gaucher cells) with a **crinkled paper** appearance in the bone marrow aspirate are highly suggestive of **Gaucher's disease**. - **Gaucher's disease** is caused by a deficiency of the lysosomal enzyme **glucocerebrosidase**, leading to the accumulation of **glucocerebroside**. *Incorrect: Hexosaminidase* - Deficiency of **hexosaminidase A** is associated with **Tay-Sachs disease**, which presents with neurological degeneration but typically **lacks hepatosplenomegaly** and bone pain. - The histological findings in Tay-Sachs disease would show neuronal storage of **GM2 gangliosides**, not Gaucher cells. *Incorrect: Sphingomyelinase* - Deficiency of **sphingomyelinase** causes **Niemann-Pick disease**, characterized by hepatosplenomegaly, neurological involvement, and interstitial lung disease, but the storage cells (foam cells) have a **foamy appearance** due to sphingomyelin accumulation, not the "crinkled paper" appearance of Gaucher cells. - While there is organomegaly, the distinct **histological features** in the image rule out Niemann-Pick disease. *Incorrect: Alpha 1,4-glucosidase* - Deficiency of **alpha 1,4-glucosidase** (acid maltase) causes **Pompe disease** (Glycogen Storage Disease Type II), which primarily affects muscle and liver with **glycogen accumulation**. - Pompe disease does not typically present with the same type of **bone pain** or the characteristic **Gaucher cells** seen in the image.

Question 2: Statins act on:

A. HMG CoA synthetase
B. HMG CoA reductase (Correct Answer)
C. HMG CoA hydratase
D. Squalene epoxidase

Explanation: ***HMG CoA reductase*** - **HMG-CoA reductase inhibitors** (statins) are the most effective and widely used class of hypolipidemic agents [1, 2, 3]. - This enzyme is the **rate-limiting step** in cholesterol biosynthesis in the liver [1, 2, 3]. *HMG CoA synthetase* - HMG-CoA synthetase is involved in the synthesis of **HMG-CoA** from acetyl-CoA and acetoacetyl-CoA. - This enzyme precedes the HMG-CoA reductase step and is **not the primary target** for cholesterol-lowering drugs. *Squalene epoxidase* - Squalene epoxidase is an enzyme involved in the later stages of the **cholesterol synthesis pathway**, specifically in converting squalene to squalene epoxide. - While inhibition of this enzyme would reduce cholesterol synthesis, it is **not the main target** of current widely used hypolipidemic agents. *HMG CoA hydratase* - HMG-CoA hydratase (also known as HMG-CoA lyase) is involved in the breakdown of HMG-CoA into **acetyl-CoA and acetoacetate** in ketogenesis. - It is **not directly involved** in the main pathway of cholesterol synthesis that is targeted by current hypolipidemic drugs.

Question 3: Which of the following anti-gout drugs acts by inhibiting the enzyme xanthine oxidase?

A. Rasburicase
B. Allopurinol (Correct Answer)
C. Probenecid
D. Sulfinpyrazone

Explanation: ***Allopurinol*** - **Allopurinol** is a purine analog that **inhibits xanthine oxidase**, thereby preventing the conversion of hypoxanthine and xanthine to uric acid. - Allopurinol is metabolized to **oxypurinol (alloxanthine)**, which acts as a **competitive inhibitor** of xanthine oxidase. - This action leads to a reduction in **serum uric acid levels**, which is crucial for preventing and treating gout attacks. *Probenecid* - **Probenecid** is a **uricosuric agent** that acts by inhibiting the reabsorption of uric acid in the renal tubules, leading to increased excretion of uric acid in the urine. - It does not affect the production of uric acid by inhibiting xanthine oxidase. *Rasburicase* - **Rasburicase** is a recombinant **uricase enzyme** that catalyzes the oxidation of uric acid to **allantoin**, a more water-soluble compound that is easily excreted by the kidneys. - It is primarily used for the management of **tumor lysis syndrome** and severe hyperuricemia, not by inhibiting xanthine oxidase. *Sulfinpyrazone* - **Sulfinpyrazone** is another **uricosuric agent** similar to probenecid, working by inhibiting the renal tubular reabsorption of uric acid. - Its mechanism of action is distinct from xanthine oxidase inhibition and focuses on enhancing uric acid excretion rather than reducing its production.

Question 4: Enzyme replacement therapy is available for which of the following lysosomal storage disorders?

A. Gaucher's disease (Correct Answer)
B. Tay-Sachs disease
C. None of the above
D. Niemann-Pick disease Type C

Explanation: ***Gaucher's disease*** - Enzyme replacement therapy (ERT) with **imiglucerase**, **velaglucerase alfa**, or **taliglucerase alfa** is a highly effective treatment for Type 1 and Type 3 Gaucher's disease - It provides the deficient enzyme **glucocerebrosidase** (β-glucosidase), which breaks down glucocerebroside, preventing its accumulation in macrophages - ERT significantly reduces hepatosplenomegaly, improves bone disease, and corrects cytopenias *Niemann-Pick disease Type C* - **No enzyme replacement therapy** is currently available for Niemann-Pick disease Type C - This disorder involves defective cholesterol trafficking, not a single enzyme deficiency amenable to replacement - Treatment is primarily **supportive** with miglustat for neurological symptoms in some cases *Tay-Sachs disease* - There is currently **no effective enzyme replacement therapy** for Tay-Sachs disease - The deficient enzyme **hexosaminidase A** cannot effectively cross the **blood-brain barrier** to reach affected neurons in the CNS - Treatment is purely **supportive and palliative** *None of the above* - This option is incorrect because **Gaucher's disease** has well-established and FDA-approved enzyme replacement therapy

Question 5: Which enzyme is irreversibly inhibited by aspirin?

A. Lipooxygenase
B. Cyclooxygenase (Correct Answer)
C. Thromboxane synthase
D. Phospholipase

Explanation: ***Cyclooxygenase*** - **Aspirin** irreversibly inhibits **cyclooxygenase (COX-1 and COX-2)** by acetylating a serine residue in the enzyme's active site. - This irreversible inhibition prevents the production of **prostaglandins, thromboxane**, and **prostacyclin**, thereby reducing inflammation, pain, fever, and platelet aggregation. *Lipooxygenase* - **Lipooxygenase** is involved in the synthesis of **leukotrienes**, which are mediators of inflammation and allergic responses. - Aspirin does not directly inhibit lipooxygenase; rather, it primarily targets the COX pathway. *Thromboxane synthase* - **Thromboxane synthase** is an enzyme downstream of COX, responsible for converting prostaglandin H2 into **thromboxane A2**. - While aspirin's effect on platelet aggregation is due to reduced thromboxane A2 synthesis via COX inhibition, it does not directly inhibit thromboxane synthase itself. *Phospholipase* - **Phospholipase A2** is responsible for releasing **arachidonic acid** from cell membrane phospholipids, which is the initial step in both the cyclooxygenase and lipooxygenase pathways. - Aspirin does not directly inhibit phospholipase A2; its action occurs later in the cascade.

Question 6: A patient presents with hyperuricemia and gout. Which enzyme's overactivity is most likely associated?

A. HGPRT
B. Xanthine oxidase
C. Adenosine deaminase
D. PRPP synthetase (Correct Answer)

Explanation: ***PRPP synthetase*** - **Overactivity** of **PRPP synthetase** leads to increased production of **5-phosphoribosyl-1-pyrophosphate (PRPP)**, a key substrate for *de novo* purine synthesis. - This increased purine synthesis results in an **overproduction of uric acid**, causing **hyperuricemia** and **gout**. *HGPRT* - **Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)** deficiency, not overactivity, is associated with hyperuricemia and gout, as seen in **Lesch-Nyhan syndrome**. - Its normal function is in the **salvage pathway**, recycling purine bases; deficiency leads to increased *de novo* purine synthesis. *Xanthine oxidase* - **Xanthine oxidase** is involved in the catabolism of purines, converting **hypoxanthine to xanthine** and then **xanthine to uric acid**. - While inhibition of this enzyme (e.g., by allopurinol) is a treatment for gout, its **overactivity alone is not typically the primary cause** of hereditary hyperuricemia; rather, altered purine metabolism leading to excess substrates for xanthine oxidase is the issue. *Adenosine deaminase* - Deficiency of **adenosine deaminase (ADA)** is primarily associated with **severe combined immunodeficiency (SCID)**, due to the accumulation of toxic metabolites that impair lymphocyte development. - It is not directly linked to the pathogenesis of **hyperuricemia** or **gout**.

Question 7: Resistance to Methotrexate develops due to?

A. Rapid proliferation of cancer cells
B. Thymidylate kinase deficiency
C. Thymidylate synthetase deficiency
D. Increased production of dihydrofolate reductase (DHFR) (Correct Answer)

Explanation: ***Increased production of dihydrofolate reductase (DHFR)*** - Methotrexate acts by inhibiting **dihydrofolate reductase (DHFR)**, an enzyme essential for **folate metabolism** and DNA synthesis. - An **increased production of DHFR** (through gene amplification or overexpression) by cancer cells allows them to bypass the drug's inhibitory effects, leading to resistance. - This is the **most common mechanism** of methotrexate resistance. *Rapid proliferation of cancer cells* - While **rapid cell proliferation** is a characteristic of cancer, it doesn't directly explain resistance to methotrexate. - Methotrexate targets fast-dividing cells (S-phase specific), so rapid proliferation often makes them **more susceptible**, not resistant, as long as the drug's mechanism is effective. *Thymidylate kinase deficiency* - **Thymidylate kinase** is involved in the phosphorylation of **thymidine** to produce **dTMP** (deoxythymidine monophosphate). - A deficiency in this enzyme would likely hinder DNA synthesis, potentially increasing sensitivity to DNA-targeting agents, rather than causing resistance to methotrexate. *Thymidylate synthetase deficiency* - **Thymidylate synthetase** converts dUMP to dTMP using **5,10-methylene-THF** as a cofactor. - Methotrexate **indirectly inhibits** thymidylate synthetase by depleting tetrahydrofolate cofactor pools through DHFR inhibition. - A **deficiency** of this enzyme would not cause resistance; rather, **increased thymidylate synthetase** expression can be an alternative resistance mechanism, though less common than DHFR overexpression.

Question 8: Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

A. Noncompetitive inhibition
B. Competitive inhibition (Correct Answer)
C. Irreversible inhibition
D. Uncompetitive inhibition

Explanation: ***Competitive inhibition*** - Atorvastatin is a **statin**, which acts as a **competitive inhibitor** of **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis. - It competes with the natural substrate, HMG-CoA, for binding to the **active site of the enzyme**, thereby reducing cholesterol production. *Uncompetitive* - **Uncompetitive inhibitors** bind only to the **enzyme-substrate complex**, not to the free enzyme. - This type of inhibition is characterized by a decrease in both **apparent Vmax** and **apparent Km**. *Noncompetitive inhibition* - **Noncompetitive inhibitors** bind to an allosteric site on the enzyme, distinct from the active site, and can bind to either the **free enzyme or the enzyme-substrate complex**. - This leads to a decrease in the **apparent Vmax** but does not affect Km. *Irreversible inhibition* - **Irreversible inhibitors** form a **strong covalent bond** with the enzyme, permanently inactivating it. - Statins do not form covalent bonds with HMG-CoA reductase; their inhibition is **reversible** upon drug discontinuation.

Question 9: HMG-CoA reductase is inhibited by:

A. Lovastatin (Correct Answer)
B. Gemfibrozil
C. Nicotinic acid
D. Clofibrate

Explanation: ***Lovastatin*** - **Lovastatin** is part of the statin class of drugs, which are potent competitive inhibitors of **HMG-CoA reductase**. - By inhibiting this enzyme, statins reduce the synthesis of **mevalonate**, a precursor to **cholesterol**, thereby lowering LDL-cholesterol levels. *Gemfibrozil* - **Gemfibrozil** is a **fibrate**, a class of drugs that primarily act by activating **peroxisome proliferator-activated receptor alpha (PPAR-α)**. - Its main effect is to decrease **triglyceride** levels and increase **HDL cholesterol**, not directly inhibit HMG-CoA reductase. *Clofibrate* - **Clofibrate** is also a **fibrate** and operates similarly to gemfibrozil by activating **PPAR-α**. - It primarily reduces **triglycerides** and has a modest effect on increasing HDL, but does not inhibit HMG-CoA reductase. *Nicotinic acid* - **Nicotinic acid** (niacin or vitamin B3) reduces hepatic synthesis of **VLDL** and inhibits the release of **fatty acids** from adipose tissue. - This leads to a decrease in **LDL cholesterol** and triglycerides, and an increase in **HDL cholesterol**, but it does not directly inhibit HMG-CoA reductase.

Question 10: Km increases, but Vmax remains same. This is which type of inhibition?

A. Uncompetitive
B. Non-competitive
C. Competitive (Correct Answer)
D. Irreversible

Explanation: ***Competitive*** - In **competitive inhibition**, the inhibitor **reversibly binds** to the **active site** of the enzyme, competing with the substrate. - This competition means that a higher substrate concentration is required to achieve half-maximal velocity, thus **increasing the Km**, while the maximum velocity (**Vmax**) remains unchanged if sufficient substrate is present. *Uncompetitive* - **Uncompetitive inhibition** involves the inhibitor binding only to the **enzyme-substrate complex**. - This type of inhibition typically leads to a **decrease in both Km and Vmax**. *Non-competitive* - In **non-competitive inhibition**, the inhibitor binds to a site other than the active site (allosteric site) on either the free enzyme or the enzyme-substrate complex. - This binding usually **decreases the Vmax** (due to reduced enzyme efficiency) but does not affect the Km (as substrate binding is not directly hindered). *Irreversible* - **Irreversible inhibition** involves the formation of a strong, often covalent, bond between the inhibitor and the enzyme, permanently inactivating it. - This type of inhibition effectively **reduces the concentration of active enzyme**, leading to a **decrease in Vmax** (as fewer enzyme molecules are available to catalyze the reaction) with varying effects on Km depending on the mechanism.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free